Aibotics, Inc. (AIBT) stock
Close on Oct 19, 2026Market cap –P/E –Yield –
Aibotics, Inc. saw revenue fall 100.0% to $0 over the twelve months to Jun 30, 2026.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$2.09M
Trading
- Previous close
- $0.00
- Open
- $0.00
- Day's range
- $0.00 – $0.00
- Volume
- 56,705,114
- Average volume (20 days)
- 32,031,090
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | AIBT | S&P 500 | Difference | AIBT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +172.7% | +0.6% | +172.1 pts | ||
| 3 months | +566.7% | +3.4% | +563.3 pts | ||
| Year to date | +20.0% | +13.3% | +6.7 pts | ||
| 1 year | -18.9% | +16.6% | −35.5 pts | ||
| 3 years | -87.4% | +86.4% | −173.7 pts | -49.8% | +23.1% |
| 5 years | -99.9% | +81.9% | −181.7 pts | -73.7% | +12.7% |
| 10 years | -94.0% | +318.9% | −412.9 pts | -24.5% | +15.4% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Aibotics filed with the SEC as exhibits to Form 8-K or 6-K
About Aibotics
Medicinal Chemicals & Botanical Products
Aibotics, Inc. develops wellness and healthcare technologies, focusing on consumer robotics and the research of psychedelics for mental health treatments. The company's consumer product offerings include the Phill Robot, an artificial-intelligence-controlled massage robot designed for home use, and Milkyway, an automated smart storage refrigerator designed for preserving breast milk. In its therapeutic activities, the company promotes studies on natural and synthetic molecules to treat conditions like depression and addiction, while sourcing naturally derived psilocybin active pharmaceutical ingredients. Its target customers and partners include retail consumers, nursing rooms, hospitals, research institutions, universities, and pharmaceutical manufacturers.
Company profile, executives and historyAibotics stock: common questions
What is Aibotics's stock price?
AIBT closed at $0.00 on Oct 19, 2026, up 42.86% on the day.
How much revenue does Aibotics make?
Aibotics reported revenue of $0 for the twelve months to Jun 30, 2026, down 100.0% from a year earlier.
Does Aibotics pay a dividend?
No. Aibotics has not paid a cash dividend over the last twelve months.
How has AIBT stock performed over the past year?
Including dividends, AIBT returned -18.9% over the past year, against +16.6% for the S&P 500.
Who are Aibotics's competitors?
Companies most similar to Aibotics by business, industry and size include TCRT, TCRG, CELZ, TLPH, CABR.
See a number that looks wrong?